Literature DB >> 10847212

Molecular genotyping of Candida species with special respect to Candida (Torulopsis) glabrata strains by arbitrarily primed PCR.

K Becker1, D Badehorn1, S Deiwick1, G Peters1, W Fegeler1.   

Abstract

A set of 46 epidemiologically related or unrelated Candida (Torulopsis) glabrata isolates from four different medical centres in Germany and Hungary, and the type strain of this species, were genetically typed by arbitrarily primed PCR (AP-PCR). The resulting band patterns of C. glabrata strains were compared with those of other species of the genus Candida including C. albicans, C. guilliermondii, C. kefyr, C. parapsilosis, C. tropicalis and C. krusei. After preliminary trials of various reaction parameters and control experiments to test the reproducibility of this method, it was found that consistently reproducible amplification patterns were obtained only when rigorously optimised and standardised reaction conditions were employed. Discriminatory abilities were studied with 29 generated 10-mer oligonucleotides of different G+C content. Typing of clinical isolates with the optimised AP-PCR protocol was then performed with the primer 50-1, with a G+C content of 50%. Sufficiently discriminatory polymorphisms were observed among the band patterns of the Candida species included. The gel electrophoresis patterns of each species showed an adequate similarity. Variations in minor bands were characteristic for comparison at the isolate level. Only three AP-PCR genotypes were identified among the clinical isolates of C. glabrata tested. Two of these genotypes were closely related and appeared to be widespread within German and Hungarian isolates. The third genotype of C. glabrata showed a distinct band pattern. With optimised, validated and standardised assay conditions, the feasibility, sensitivity and rapidity of AP-PCR may offer a discriminatory method for genotyping of yeasts in epidemiological studies, as well as in the control of nosocomial infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10847212     DOI: 10.1099/0022-1317-49-6-575

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  6 in total

1.  Genetic diversity among clinical isolates of Candida glabrata analyzed by randomly amplified polymorphic DNA and multilocus enzyme electrophoresis analyses.

Authors:  Xavier M Boldo; Lourdes Villa-Tanaca; Gerardo Zúñiga; César Hernández-Rodríguez
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

2.  Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.

Authors:  James S Lewis; Nathan P Wiederhold; Brian L Wickes; Thomas F Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

3.  Isolation and characterization of a species-specific DNA fragment for identification of Candida (Torulopsis) glabrata by PCR.

Authors:  K Becker; D Badehorn; B Keller; M Schulte; K H Böhm; G Peters; W Fegeler
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

4.  Loss of in vitro resistance in Candida glabrata following discontinuation of fluconazole prophylaxis in a hematopoietic stem cell transplantation patient.

Authors:  Steven D Westbrook; Nathan P Wiederhold; Ana C Vallor; Susann Kotara; Stella Bernardo; Samuel A Lee; William R Kirkpatrick; Juan J Toro; Cesaro Freytes; Thomas F Patterson; Spencer W Redding
Journal:  Med Mycol       Date:  2010-05       Impact factor: 4.076

5.  Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

Authors:  George R Thompson; Nathan P Wiederhold; Ana C Vallor; Nyria C Villareal; James S Lewis; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

6.  Evaluation of Polymorphic Locus Sequence Typing for Candida glabrata Epidemiology.

Authors:  Santosh Katiyar; Eric Shiffrin; Celeste Shelton; Kelley Healey; John-Paul Vermitsky; Tom Edlind
Journal:  J Clin Microbiol       Date:  2016-02-03       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.